Key Financial Figures - Quarter Ended September 30, 2026
- Revenue from operations: ₹4,754.83 lakh (₹47.55 crore)
- Other income: ₹315.03 lakh
- Total income: ₹5,069.86 lakh
- Total expenses: ₹4,905.95 lakh
- Profit before tax: ₹163.91 lakh
- Tax expense: ₹14.39 lakh
- Profit after tax: ₹149.52 lakh (₹1.50 crore)
- Basic and diluted EPS: ₹0.16 (not annualized)
- Paid-up equity share capital: ₹9,286.07 lakh
Key Financial Figures - Half Year Ended September 30, 2026
- Revenue from operations: ₹10,353.42 lakh
- Other income: ₹334.19 lakh
- Total income: ₹10,687.61 lakh
- Total expenses: ₹9,408.07 lakh
- Profit before tax: ₹1,279.54 lakh
- Tax expense: ₹456.47 lakh
- Profit after tax: ₹823.07 lakh
- Basic and diluted EPS: ₹0.93 (not annualized)
Comparative Performance
- Q2 FY26 restated revenue: ₹1,728.09 lakh vs Q2 FY27: ₹4,754.83 lakh
- Q2 FY26 restated net loss: ₹(1,428.08) lakh vs Q2 FY27 net profit: ₹149.52 lakh
- H1 FY26 restated revenue: ₹2,955.30 lakh vs H1 FY27: ₹10,353.42 lakh
- H1 FY26 restated net loss: ₹(3,132.21) lakh vs H1 FY27 net profit: ₹823.07 lakh
Merger Impact (Note 4)
The company completed merger with Innovassynth Technologies (India) Limited (ITIL) effective from appointed date October 1, 2024, approved by NCLT on November 14, 2025. The merger resulted in:
- Issuance of 4,74,65,031 equity shares (face value ₹10 each) at issue price of ₹29.39 each
- Increase in share capital by ₹13,949.97 lakh (face value ₹4,746.50 lakh + securities premium ₹9,203.47 lakh)
- Comparative figures for September 2025 have been restated to include ITIL's operations
Rights Issue (Note 5)
- Board approved rights issue of 1,74,11,380 equity shares at ₹40 per share (₹30 premium) aggregating ₹6,964.55 lakh
- Received BSE in-principle approval on April 20, 2026
- Final letter of offer submitted April 23, 2026
- Ratio: 3 rights shares for every 13 existing shares
- Record date: April 29, 2026
- Allotment completed: May 19, 2026
Balance Sheet Position (as at September 30, 2026)
- Total assets: ₹28,862.52 lakh
- Property, plant and equipment: ₹12,395.45 lakh
- Inventories: ₹6,330.05 lakh
- Trade receivables: ₹3,141.82 lakh
- Cash and cash equivalents: ₹149.69 lakh
- Total equity: ₹17,173.96 lakh
- Total liabilities: ₹11,688.56 lakh
- Borrowings: ₹3,014.66 lakh (current ₹2,716.85 lakh + non-current ₹297.81 lakh)
Cash Flow Statement (Six months ended September 30, 2026)
- Net cash from operating activities: ₹2,004.79 lakh
- Net cash used in investing activities: ₹(1,175.38) lakh
- Net cash from financing activities: ₹1,308.47 lakh
- Net increase in cash: ₹2,137.87 lakh
Other Matters
- The main business is manufacturing of specialty chemicals and pharmaceutical intermediates
- The financial results were reviewed by the audit committee and approved by the board on November 2, 2026
- Statutory auditors P G Bhagwat LLP issued an unmodified review report
- Exceptional items of ₹21.40 lakh (Q2 FY25) and ₹21.50 lakh (H1 FY25) related to merger expenses